Il Dottor Maurea da sempre si occupa di ricerca scientifica e studi di settore collocando il proprio lavoro al centro delle attuali conoscenze cardiologiche, con le finalità di introdurre progresso nei sistemi di cura e delle innovazioni terapeutiche nel contesto di una riflessione critica nel campo della Cardioncologia.
-
Pubblicazioni Impattate
- 1. Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C, Maurea N. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathwaysFront Cardiovasc Med. 2022 Sep 8;9:930797. doi: 10.3389/fcvm.2022.930797. eCollection 2022.
- 2. Berretta M, Morra A, Taibi R, Monari F, Maurea N, Ippolito M, Tirelli U, Fiorica F, Montella L, Facchini G, Quagliariello V, Montopoli M. Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature Front Pharmacol. 2022 Jun 16;13:867907. doi: 10.3389/fphar.2022.867907. eCollection 2022.
- 3. Berretta M, Quagliariello V, Bignucolo A, Facchini S, Maurea N, Di Francia R, Fiorica F, Sharifi S, Bressan S, Richter SN, Camozzi V, Rinaldi L, Scaroni C, Montopoli M. The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies Antioxidants (Basel). 2022 May 30;11(6):1090. doi: 10.3390/antiox11061090.
- 4. Bisceglia I, Canale ML, Gallucci G, Turazza FM, Lestuzzi C, Parrini I, Russo G, Maurea N, Quagliariello V, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Moreo A, Geraci G, Gabrielli D, Gulizia MM, Oliva F, Colivicchi F. Corrigendum: Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story. Front Cardiovasc Med. 2022 May 13;9:903766. doi: 10.3389/fcvm.2022.903766. eCollection 2022. PMID: 35647054
- 5. Canale ML, Turazza F, Lestuzzi C, Parrini I, Camerini A, Russo G, Colivicchi F, Gabrielli D, Gulizia MM, Oliva S, Tarantini L, Maurea N, Rigacci L, Petrolati S, Casolo G, Bisceglia I..Corrigendum: Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey - Front Cardiovasc Med. 2022 May 10;9:920605. doi: 10.3389/fcvm.2022.920605. eCollection 2022
- 6. Vianello C, Cocetta V, Catanzaro D, Dorn GW 2nd, De Milito A, Rizzolio F, Canzonieri V, Cecchin E, Roncato R, Toffoli G, Quagliariello V, Di Mauro A, Losito S, Maurea N, Cono S, Sales G, Scorrano L, Giacomello M, Montopoli M. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death Dis. 2022 Apr 22;13(4):398. doi:10.1038/s41419-022-04741-9. PMID: 35459212; PMCID: PMC9033831.
- 7. Canale ML, Coviello K, Solarino G, Del Meglio J, Simonetti F, Venturini E, Camerini A, Maurea N, Bisceglia I, Tessa C, Casolo G. Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology. Front Cardiovasc Med. 2022 Mar 1;9:801143. doi: 10.3389/fcvm.2022.801143. PMID: 35299980; PMCID: PMC8923038
- 8. Di Cicco C, Vecchione R, Quagliariello V, Busato A, Tufano I, Bedini E, Gerosa M, Sbarbati A, Boschi F, Marzola P, Maurea N, Netti PA. Biocompatible, photo-responsive layer-by-layer polymer nanocapsules with an oil core: in vitro and in vivo study. J R Soc Interface. 2022 Feb;19(187):20210800. doi: 10.1098/rsif.2021.0800. Epub 2022 Feb 23. PMID: 35193388; PMCID: PMC8867280.
- 9. Bisceglia I, Canale ML, Gallucci G, Turazza FM, Lestuzzi C, Parrini I, Russo G, Maurea N, Quagliariello V, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Moreo A, Geraci G, Gabrielli D, Gulizia MM, Oliva F, Colivicchi F. Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story- Front Cardiovasc Med. 2022 Jan 28;9:821193. doi: 10.3389/fcvm.2022.821193. eCollection 2022.
- 10. Nicola Maurea, Vincenzo Quagliariello, Andrea Paccone, Michelino De Laurentiis, Simona Buccolo, Martina Iovine, and Gerardo Botti ; Cytoprotective effects of spirulina extract against doxorubicin‐induced cardiotoxicity: Biochemical evidences and translational perspectives in cardio-oncology. Journal of Clinical Oncology 2021 39:15_suppl, e15042-e15042 vedi
- 11. Quagliariello V, Paccone A, Iovine M, Cavalcanti E, Berretta M, Maurea C, Canale ML, Maurea N., Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19 , Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6797-6812. doi: 10.26355/eurrev_202111_27124
- 12. Bisceglia I, Gabrielli D, Canale ML, Gallucci G, Parrini I, Turazza FM, Russo G, Maurea N, Quagliariello V, Lestuzzi C, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Gulizia MM, Colivicchi F., ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO) G Ital Cardiol (Rome). 2021 Oct;22(10):800-825. doi: 10.1714/3666.36511.
- 13. V Quagliariello, A Bonelli, A Paccone, S Buccolo, M Iovine, G Conforti, G Botti, N Maurea, Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1; European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2839, https://doi.org/10.1093/eurheartj/ehab724.2839 Published: 14 October 2021 vedi
- 14. V Quagliariello, A Bonelli, A Paccone, S Buccolo, M Iovine, G Botti, N Maurea; Oxidized Low-Density Lipoproteins increases nivolumab-induced cardiotoxicity through TLR4/NF-KB and NLRP3 pathways. European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2837, https://doi.org/10.1093/eurheartj/ehab724.2837 Published: 14 October 2021 vedi
- 15. Bisceglia I, Gabrielli D, Canale ML, Gallucci G, Parrini I, Turazza FM, Russo G, Maurea N, Quagliariello V, Lestuzzi C, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Gulizia MM, Colivicchi FANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO) - Eur Heart J Suppl. 2021 Aug 26;23(Suppl C):C128-C153. doi: 10.1093/eurheartj/suab067
- 16. Ronchi A, Grauso F, Zito Marino F, Quagliariello V, Maurea N, Facchini G, Montopoli M, Franco R, Berretta M, Messalli EM. Endocannabinoid system expression in ovarian epithelial tumors according to the dualistic model of ovarian carcinogenesis, Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4678-4686. doi: 10.26355/eurrev_202107_26378.
- 17. Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , Cardiovasc Diabetol. 2021 Jul 23;20(1):150. doi: 10.1186/s12933-021-01346-y
- 18. Canale ML, Turazza F, Lestuzzi C, Parrini I, Camerini A, Russo G, Colivicchi F, Gabrielli D, Gulizia MM, Oliva S, Tarantini L, Maurea N, Rigacci L, Petrolati S, Casolo G, Bisceglia I. Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey Front Cardiovasc Med. 2021 Jun 16;8:677544. doi: 10.3389/fcvm.2021.677544. eCollection 2021.
- 19. Quagliariello V, Berretta M, Buccolo S, Iovine M, Paccone A, Cavalcanti E, Taibi R, Montopoli M, Botti G, Maurea N. Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression Front Oncol. 2021 Jun 11;11:680758. doi: 10.3389/fonc.2021.680758. eCollection 2021
- 20. Quagliariello V, D'Aiuto G, Iaffaioli RV, Berretta M, Buccolo S, Iovine M, Paccone A, Cerrone F, Bonanno S, Nunnari G, Laganà N, Botti G, Maurea N. Reasons why COVID-19 survivors should follow dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations: from hyper-inflammation to cardiac dysfunctions Eur Rev Med Pharmacol Sci. 2021 May;25(10):3898-3907. doi: 10.26355/eurrev_202105_25957
- 21.Carbone A, Bottino R, Russo V, D'Andrea A, Liccardo B, Maurea N, Quagliariello V, Cimmino G, Golino P - Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports - J Cardiovasc Pharmacol 2021 Jul 1;78(1):e20-e29. doi: 10.1097/FJC.0000000000001026
- 22.Nicola Maurea, Vincenzo Quagliariello, Andrea Paccone, Michelino De Laurentiis, Simona Buccolo, Martina Iovine, Gerardo Botti, Cytoprotective effects of spirulina extract against doxorubicin‐induced cardiotoxicity: Biochemical evidences and translational perspectives in cardio-oncology. DOI: 10.1200/JCO.2021.39.15_suppl.e15042 Journal of Clinical Oncology 39, no. 15_suppl vedi
- 23.Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S- Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports- Cancer Immunol Immunother. 2021 Apr 20.
- 24.Berretta M, Quagliariello V, Maurea N, Di Francia R, Sharifi S, Facchini G, Rinaldi L, Piezzo M, Manuela C, Nunnari G, Montopoli M -Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies- Antioxidants (Basel). 2020 Nov 26;9(12):1182
- 25.Quagliariello V, Bonelli A, Caronna A, Conforti G, Iovine M, Carbone A, Berretta M, Botti G, Maurea N. SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer PatientsCancers (Basel). 2020 Nov 10;12(11):3316
- 26.Barbieri A, Robinson N, Palma G, Maurea N, Desiderio V, Botti G Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer Front Immunol. 2020 Sep 30;11:588724.
- 27.Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, Lombari MC, Conforti G, Berretta M, Botti G, Maurea N NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells - Int J Mol Sci. 2020 Oct 21;21(20):7802.
- 28.Gulizia Chairperson MM, Parrini Co-Chairperson I, Colivicchi Co-Chairperson F, Bisceglia I, Caiazza F, Gensini GF, Mureddu GF, Santomauro M, Ageno W, Ambrosetti M, Aspromonte N, Barni S, Bellocci F, Caldarola P, Carletti M, De Luca L, Di Fusco SA, Di Lenarda A, Di Nisio M, Domenicucci S, Enea I, Francese GM, Lestuzzi C, Lucà F, Maurea N, Nassiacos D, Pedretti RFE, Pusineri E, Roscio G, Rossini R, Russo A, Volterrani M, Gabrielli Co-Chairperson D. - [HCF-ANMCO/AICPR/GIEC/ITAHFA/SICOA/SICP/SIMG/SIT Cardiological Societies Council Consensus document: Anticoagulant therapy in venous thromboembolism and atrial fibrillation of the patient with cancer. Current knowledge and new evidence] - G Ital Cardiol (Rome). 2020 Sep;21(9):687-738
- 29.Vincenzo Quagliariello , Margherita Passariello , Domenica Rea , Antonio Barbieri , Martina Iovine , Annamaria Bonelli , Antonietta Caronna , Gerardo Botti , Claudia De Lorenzo, Nicola Maurea Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models- J Pers Med 2020 Oct 19;10(4):E179.
- 30.Avallone, A., Piccirillo, M.C., Di Gennaro, E., Romano, C, Calabrese, F., Roca, M.S., Tatangelo, F., Granata, V, Cassata, A., Cavalcanti, E., Maurea, N., Maiolino, P., Silvestro, L., De Stefano, A., Giuliani, F., Rosati, G, Tamburini, E., Aprea, P, Vicario, V Nappi, A., Vitagliano, C., Casaretti, R, Leone, A., Petrillo, A., Botti, G., Delrio, P., Izzo, F, Perrone, F, Budillon, A.- Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol - Therapeutic Advances in Medical Oncology
- 31.Volume 12, 2020
- 32.Quagliariello, V. Bonelli, A. Caronna, A. Lombari, M.C. Conforti, G. Libutti, M. Iaffaioli, R.V. Berretta, M.Botti, G. Maurea, N. - SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? - European Review for Medical and Pharmacological Sciences Volume 24, Issue 17, 2020, Pages 9169-9171
- 33.Quagliariello, V.Vecchione, R. De Capua, A.Lagreca, E.Iaffaioli, R.V.Botti, G. Netti, P.A.Maurea, N- Nano-encapsulation of coenzyme q10 in secondary and tertiary nano-emulsions for enhanced cardioprotection and hepatoprotection in human cardiomyocytes and hepatocytes during exposure to anthracyclines and trastuzumab - International Journal of Nanomedicine - Volume 15, 2020, Pages 4859-4876
- 34.Barbieri, A., Robinson, N.,Palma, G. Maurea, N. Desiderio, V., Botti, G. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?—Lessons Learned From Cancer - Frontiers in Immunology Volume 11, 30 September 2020, Article number 588724
- 35.Canale, M.L.Camerini, A.Casolo, G.Lilli, A.Bisceglia, I.Lestuzzi, C.Del Meglio, J.Puccetti, C.Camerini, L.Amoroso, D.,Maurea, N. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy- Advances in Therapy 37(7), pp. 3178-3184 2020
- 36.Berretta, M Bignucolo A. Di Francia R. Comello F Facchini, G, Ceccarelli, M, Iaffaioli, R.V. Quagliariello, V.Maurea, N- Resveratrol in cancer patients: From bench to bedside - International Journal of Molecular Sciences 2020 Volume 21, Issue 8, 2 April 2020, Article number 2945
- 37.Calcagno V, Vecchione R, Quagliariello V, Marzola P, Busato A, Giustetto P, Profeta M, Gargiulo S, Cicco CD, Yu H, Cassani M, Maurea N, Mancini M, Pellegrino T, Netti PA. Oil Core-PEG Shell Nanocarriers for In Vivo MRI Imaging. Adv Healthc Mater. 2019 Feb;8(3):e1801313. doi: 10.1002/adhm.201801313. Epub 2019 Jan 7.
- 38.Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019.
- 39.Quagliariello V, Coppola C, Mita DG, Piscopo G, Iaffaioli RV, Botti G, Maurea N. Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts. Environ Toxicol Pharmacol. 2019 Jul;69:1-8. doi: 10.1016/j.etap.2019.03.006. Epub 2019 Mar 7.
- 40.Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V. Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells. Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28.
- 41.Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N.Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.Int J Cardiol. 2019 Oct 1;292:171-179. doi: 10.1016/j.ijcard.2019.05.028. Epub 2019 May 17.
- 42.Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, Iaffaioli RV, Botti G, Netti PA, Maurea N. Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity. Nutrients. 2018 Sep 14;10(9)
- 43.Riccio G, Antonucci S, Coppola C, D’Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N. Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production. Front. Physiol. 2018 Feb 6; 9:38
- 44.De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of Ranolazine. OncoTargets and therapy, 2018 Apr 19; 11:2241-2250
- 45.Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators. Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy. 2018;63(2):55-63.
- 46.Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2017 Dec 6;63:135-143.
- 47.Fotticchia T, Vecchione R, Scognamiglio PL, Guarnieri D, Calcagno V, Di Natale C, Attanasio C, De Gregorio M, Di Cicco C, Quagliariello V, Maurea N, Barbieri A, Arra C, Raiola L, Iaffaioli RV, Netti PA. Enhanced Drug Delivery into Cell Cytosol via Glycoprotein H-Derived Peptide Conjugated Nanoemulsions. ACS Nano. 2017 Oct 24;11(10):9802-9813
- 48.Luigi Tarantini (Coordinator), Michele Massimo Gulizia, FACC, FESC (Coordinator), Andrea Di Lenarda, FACC, FESC (Coordinator), Nicola Maurea, FACC, FESC (Coordinator), Maurizio Giuseppe Abrignani, Irma Bisceglia, Daniella Bovelli, Luisa De Gennaro, Donatella Del Sindaco, Francesca Macera, Iris Parrini, Donatella Radini, Giulia Russo, Angela Beatrice Scardovi, and Alessandro Inno. [ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary]. European Heart Journal Supplements (2017) 19 (Supplement D), D370–D379.
- 49.Maurea N, Ragone G, Coppola C, Caronna A, Tocchetti CG, Agozzino L, Apice G, Iaffaioli RV. Intracardiac metastasis originated from chondrosarcoma. J Cardiovasc Med (Hagerstown). 2017 May;18(5):385-388
- 50.Coppola C, Riccio G, Barbieri A, Monti MG, Piscopo G, Rea D, Arra C, Maurea C, De Lorenzo C, Maurea N. Antineoplastic related cardiotoxicity, morphofunctional aspects in murine model: contribution of the new tool 2D-speckle tracking. Oncotarget and therapy 2016 Nov 2;9:6785-6794.
- 51.Rea D, Coppola C, Barbieri A, Monti MG, Misso G, Palma G, Bimonte S, Zarone MR, Luciano A, Liccardo D, Maiolino P, Cittadini A, Ciliberto G, Arra C, Maurea N. Strain Analysis in the Assessment of a Mouse Model of Cardiotoxicity due to Chemotherapy: Sample for Preclinical Research. In Vivo. 2016 May-Jun;30(3):279-90.
- 52.Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G. A reccommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S93-S104.
- 53.Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G. Pathophysiology of Cardiotoxicity from Target Therapy and Angiogenesis Inhibitors. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S19-26
- 54.Spallarossa P, Maurea N, Cadeddu C, Mele D, Tocchetti CG, Pagliaro P, Madonna R, Monte I, Novo G, Pepe A, Zito C, Mercuro G. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S84-92
- 55.Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, Zito C, Maurea N, Spallarossa P. Pathophysiology of anthracycline cardiotoxicity. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S3-S11
- 56.Riccio G, Coppola C, Piscopo G, Capasso I, Maurea C, Esposito E, De Lorenzo C, Maurea N. Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline Type I from Type II. Cosmi F, Di Giulio P, Masson S, Finzi A, Marfisi RM, Cosmi D, Scarano M, Tognoni G, Maggioni AP, Porcu M, Boni S, Cutrupi G, Tavazzi L, Latini R; GISSI-HF Investigators. Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. Circ Heart Fail. 2015 May;8(3):428-37
- 57.Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Barberio MT, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial). BMC Cancer. 2014 Nov 24;14(1):875
- 58.Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G. Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. Diabetol Metab Syndr. 2014 Sep 26;6(1):105
- 59.Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L; ICARO (Italian CARdio-Oncological) Network. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6
- 60.Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, De Lorenzo C, Arra C, Condorelli G, Di Lisa F, Maurea N. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014 Apr;16(4):358-66
- 61.D'Avino C, Paciello R, Riccio G, Coppola M, Laccetti P, Maurea N, Raines RT, De Lorenzo C. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. Protein Eng Des Sel. 2014 Mar;27(3):83-8.
- 62.Askevold ET, Aukrust P, Nymo SH, Lunde IG, Kaasbøll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H, Fiane A, Dahl CP, Finsen AV, Vinge LE, Christensen G, Yndestad A, Gullestad L, Latini R, Masson S, Tavazzi L; GISSI-HF Investigators, Ueland T.The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure.J Intern Med. 2014 Jun;275(6):621-30
- 63.Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M, D'Aiuto M, Frasci G, Botti G, Grimaldi M, Cavalcanti E, Esposito G, Fucito A, Brillante G, D'Aiuto G, Ciliberto G. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.Trials. 2013 Aug 28;14(1):273
- 64.Capasso I, Esposito E, Pentimalli F, Montella M, Crispo A, Maurea N, D Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D Aiuto G, Ciliberto G, Giordano A. Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: national cancer institute of Naples experience. J Exp Clin Cancer Res. 2013 Mar 14;32(1):14
- 65.Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, Giudice A, Iaffaioli RV, Arra C, Maurea N. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013 May; 15(5):482-9.
- 66.Gallucci G, Tartarone A, Tocchetti CG, Bochicchio AM, Coccaro M, Capobianco A, Maurea N, Improta G, Zupa A, Aieta M. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. Future Oncol. 2013 Jan;9(1):127-33
- 67.Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F, Ceccherini R, Bovelli D, Lestuzzi C, Cioffi G, Lestuzzi C, Fioretti SO, Giotta F, Latorre A, Tarantini L, Russo P, Sardina G, Catania G, Tuccia F, Laveder F, Faggiano P, Triggiani M, Simoncini E, Severini D, Di Tano G, Generali D, Gabrielli D, Pennacchietti L, Cardinali L, Maurea N, Lombari MC, De Laurentis M, Pacilio C, Gori S, Alunni G, Carluccio E, Boccardi L, Fini F, Pulignano G, Bovelli D, De Bonis P, Nunzi M, Sabatini S, Russo G, Di Lenarda A, Ceccherini R; ICARO (Italian CARdio-Oncologic) Network. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012 Dec;23(12):3058-63
- 68.Oliva S, Cioffi G, Frattini S, Simoncini EL, Faggiano P, Boccardi L, Pulignano G, Fioretti AM, Giotta F, Lestuzzi C, Maurea N, Sabatini S, Tarantini L; Italian Cardio-Oncological Network. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist. 2012;17(7):917-24
- 69.Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012 Feb;18(2):113-9
- 70.Tocchetti CG, Ragone G, Coppola C, Rea D, Piscopo G, Scala S, De Lorenzo C, Iaffaioli RV,Arra C, Maurea N. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail. 2012 Feb;14(2):130-7
- 71.Tocchetti CG, Coppola C, Arra C, Maurea N. Early identification of left ventricular dysfunction induced by trastuzumab. J Am Coll Cardiol. 2011 Dec 13;58(25): 2698-9
- 72.Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. 2012 Jun;133(2):511-21
- 73.Tocchetti CG, Lombari MC, Librera M, Ascierto PA, Maurea N. Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. Eur J Echocardiogr. 2011 Aug;12(8):636
- 74.Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, Frasci G, Maurea N, Esposito G, Pedicini T, Vecchione A, D'Aiuto G, Giordano A. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience.Cancer Biol Ther. 2010 Dec 15;10(12):1240-3. Epub 2010 Dec 15.
- 75.Giudice A, Caraglia M, Marra M, Montella M, Maurea N, Abbruzzese A, Arra C. Circadian rhythms, adrenergic hormones and trafficking of hematopoietic stem cells. Expert Opin Ther Targets. 2010 May;14(5):567-75. doi: 10.1517/14728221003769887
- 76.Maurea N, Coppola C, Ragone G, Frasci G, Bonelli A, Romano C, Iaffaioli RV. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. J Cardiovasc Med (Hagerstown). 2010 Dec;11(12):861-8. doi: 10.2459/JCM.0b013e328336b4c1.
- 77.Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8. Epub 2008 Aug 29.
- 78.Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1231-9. doi: 10.1016/S0140-6736(08)61240-4. Epub 2008 Aug 29.
- 79.De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.BMC Cancer. 2007 Mar 20;7:50.
- 80.Maurea N, Mollo A, Boccalatte M, Esposito S, Agozzino L, Bellitti R. Lipoma of the heart: a case report. Ital Heart J. 2001 Aug;2(8):621-3.
- 81.Vigorito C, Giordano A, Maurea N, Casaburi E, Maurelli B, Farese N, Longobardi G, Abete P, Rumolo S, Rengo F.Cardiologia.Effects of histamine on coronary circulation in man. 1988 Feb;33(2):195-200
- 82.Vigorito C, Giordano A, De Caprio L, Vitale DF, Maurea N, Silvestri P, Tuccillo B, Ferrara N, Marone G, Rengo F. Effects of histamine on coronary hemodynamics in humans: role of H1 and H2 receptors. J Am Coll Cardiol. 1987 Dec;10(6):1207-13.
- 83.Vigorito C, Giordano A, Maurea N, Tuccillo B, Rengo F. Rapid relief of spontaneous angina by intraventricular diltiazem: systemic and regional coronary haemodynamic determinants. Eur Heart J. 1987 Aug;8(8):910-1.
- 84.Vigorito C, Giordano A, De Caprio L, Vitale D, Ferrara N, Tuccillo B, Maurea N, Rispoli M, Rengo F. Direct coronary vasodilator effects of intracoronary histamine administration in humans. J Cardiovasc Pharmacol. 1986 Sep-Oct;8(5):933-9.
- 85.Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI‐HF Investigators. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.J Am Heart Assoc. 2017 Jul 5;6(7). pii: e005156. doi: 10.1161/JAHA.116.005156.
- 86.Cosmi F, Di Giulio P, Masson S, Finzi A, Marfisi RM, Cosmi D, Scarano M, Tognoni G, Maggioni AP, Porcu M, Boni S, Cutrupi G, Tavazzi L, Latini R; GISSI-HF Investigators. Regular wine consumption in chronic heart failure: impact on outcomes, quality of life, and circulating biomarkers. Circ Heart Fail. 2015 May;8(3):428-37. doi: 10.1161/Circ Heart Failure.114.002091. Epub 2015 Apr 29.